Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...

The Inceptiv data give Medtronic more evidence as it tries to increase sales of a product that drove double-digit growth at ...

Medtronic (NYSE: MDT) today announced 12-month data demonstrating the benefits of its Inceptiv closed-loop spinal cord stimulator (CL-SCS).

Nearly a quarter of adults in the U.S. have chronic pain, but a new UC Davis study shows a concerning drop in residents ...

Peripheral Nerve Stimulators market Insights: The rise in neurological and pain management treatments fuels the adoption of peripheral nerve stimulators.

Discover the latest FDA-cleared orthopedic and spine devices and technologies, including robotics, implants, and bone graft systems.

Notable achievements include Vietnam's first successful treatment of an epilepsy patient using Deep Brain Stimulation and the ... improving surgical outcomes in spine, hernia, thoracic and ...

SAN FRANCISCO—While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as ...

“Case outcomes (settlement, plaintiff or defendant ruling) did not statistically vary based on the SCS (spinal cord stimulator) manufacturer type-St. Jude, Boston Scientific Corp., or Medtronic.

Multiple FDA-approved SCS systems, such as Nevro’s Senza and HFX iQ, as well as Medtronic’s Vanta, Intellis, and Inceptiv systems are available, each offering different features to cater to individual ...

Medtronic's adjusted earnings per share grew 8%. While top-line and bottom-line growth hasn't been impressive, there's reason for optimism that this could grow faster. Neuroscience leads the way A ...